Skip to main content
TipRanks
Go Ultimate75% OFF

Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

0 Followers
SE:CLS.B

Clinical Laserthermia Systems AB Class B

(Nasdaq OMX AB:CLS.B)

Select Model
Rating:38Underperform
Price Target:SEK 1.50â–¼(-7.86% Downside)
Action:reiterated
Date:11/03/26

The overall score is severely depressed by the company's fundamental weakness. The primary drag is the financial performance, marked by declining revenue, negative margins, and ongoing cash burn that threatens the debt-free balance sheet. This is compounded by a persistent technical downtrend and a negative P/E ratio that underscores the lack of profitability. The company's survival hinges on achieving profitability or securing further capital.

Positive Factors
Debt-Free Balance SheetZero reported debt materially reduces refinancing pressure and interest-related financial risk while the company continues to operate at a loss. Positive equity provides a solvency buffer, giving management more flexibility to pursue commercialization and absorb operating volatility over the next several quarters.
Negative Factors
Declining RevenueRevenue contraction indicates that commercial demand or realized sales have not yet established a durable growth trajectory. Lower volume also makes it harder to absorb fixed operating costs, limiting the company’s ability to convert its platform and clinical technology into sustainable earnings.

Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:CLS.B-75.85%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 78.99M
Dividend Yield
―
Average Volume (3M)
71.44K
Price to Earnings (P/E)
-1.2
Beta (1Y)
0.38
Revenue Growth
-47.42%
EPS Growth
44.01%
Country
Sweden
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The...

How the Company Makes Money

CLS generates revenue primarily from selling its laser ablation/thermotherapy platform and associated consumables used in clinical procedures. Key revenue streams typically include: (1) system/platform sales (capital equipment) to hospitals and clini...

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Financial health is critically weak. Revenue declined 12% with negative gross profit, and the company remains deeply unprofitable. Although the balance sheet is debt-free, equity is eroding rapidly due to persistent losses, and cash flow remains negative, indicating a continued cash burn that will likely require additional funding.

Income Statement

22Negative

Balance Sheet

38Negative

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.56M17.49M18.78M8.27M6.27M2.25M
Gross Profit-4.10M-29.00M10.42M3.00M-2.79M-3.63M
EBITDA-37.95M-26.41M-44.76M-68.41M-57.84M-57.05M
Net Income-39.49M-41.61M-47.62M-79.79M-70.66M-63.62M
Balance Sheet
Total Assets66.57M76.49M78.56M57.73M49.51M66.74M
Cash, Cash Equivalents and Short-Term Investments3.87M21.55M22.51M15.33M10.59M31.17M
Total Debt00224.00K454.00K30.68M273.50K
Total Liabilities22.07M10.00M12.88M14.20M41.64M45.55M
Stockholders Equity47.84M69.67M68.72M45.77M9.22M21.79M
Cash Flow
Free Cash Flow-32.35M-36.00M-58.92M-71.95M-71.25M-66.73M
Operating Cash Flow-25.04M-33.20M-56.45M-66.45M-70.69M-66.17M
Investing Cash Flow-7.31M-2.80M-7.47M-5.50M-886.00K-408.00K
Financing Cash Flow20.02M35.04M71.10M76.69M61.84M85.88M

Clinical Laserthermia Systems AB Class B Technical Analysis

Technical Analysis SentimentNegative
Last Price1.63

Price Trends

50DMA1.79Negative
100DMA2.06Negative
200DMA3.45Negative

Market Momentum

MACD-0.03Positive
RSI32.79Neutral
STOCH22.82Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 1.63 is below the 20-day moving average (MA) of 1.75, below the 50-day MA of 1.79, and below the 200-day MA of 3.45, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 32.79 is Neutral, neither overbought nor oversold. The STOCH value of 22.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:CLS.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CRAD.BSE:CRAD.B64NeutralSEK 827.29M17.4113.23%0.41%-8.76%103.87%
SE:RAY.BSE:RAY.B63NeutralSEK 5.98B28.9522.61%2.29%3.16%-5.78%
SE:PAXSE:PAX57NeutralSEK 1.55B-306.14-1.22%―34.05%-144.96%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SPAGOSE:SPAGO42NeutralSEK 35.13M-1.10-87.37%―-97.52%31.31%
SE:SPECSE:SPEC40UnderperformSEK 19.12M-0.11-57.15%――78.15%
SE:CLS.BSE:CLS.B38UnderperformSEK 78.99M-1.21-66.41%―-47.42%44.01%

* Healthcare Sector Average

Performance Comparison

-50%0%SE:CLS.BSE:PAXSE:RAY.BSE:SPECSE:CRAD.BSE:SPAGODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CLS.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CLS.BClinical Laserthermia Systems AB Class B1.63-5.10-75.81%
SE:PAXPaxman AB66.804.807.74%
SE:RAY.BRaySearch Laboratories AB Class B174.30-36.24-17.21%
SE:SPECSpectraCure AB0.01-0.12-89.92%
SE:CRAD.BC-Rad AB Class B24.50-10.09-29.18%
SE:SPAGOSpago Nanomedical AB0.04-0.06-56.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026